258 results on '"Pharmacodynamic study"'
Search Results
152. Dose escalation and pharmacodynamic study of intravenous adminstration of Reolysin, a live replication competent RNA virus in patients with advanced solid tumors
153. Phase I, pharmacokinetic, and pharmacodynamic study of carboplatin and topotecan administered in two different schedules
154. 282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors
155. Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib
156. A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
157. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
158. Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study
159. A Novel Partial 5HT3 Agonist DDP733 after a Standard Refluxogenic Meal Reduces Reflux Events: A Randomized, Double-Blind, Placebo-Controlled Pharmacodynamic Study
160. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
161. pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)
162. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors
163. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies
164. 96 DYAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING PHARMACODYNAMIC STUDY OF SORAFENIB IN METASTATIC RENAL CELL CARCINOMA: PRELIMINARY RESULTS OF A RANDOMIZED, PHASE II TRIAL
165. 298 POSTER Oxaliplatin induces the expression of genes involved in capecitabine activation: preliminary results of a pharmacodynamic study in esophageal cancer
166. 26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies
167. 181 POSTER A Phase Ib safety and pharmacodynamic study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
168. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] in combination with gemcitabine [2’,2’ difluorodeoxycytidine] in patients with advanced malignancies
169. Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors
170. An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors
171. Phase II pharmacodynamic study of the fibroblast activation protein inhibitor Val-boro-Pro in patients with metastatic colorectal cancer
172. The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women
173. Pharmacodynamic study of gefitinib in skin from patients with recurrent carcinoma of head + neck
174. A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98
175. A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients
176. P-106 Pharmacodynamic study of 5-azacytidine
177. 787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839
178. A phase 1, randomized, double-blind, placebo-controlled dose-escalating, safety, tolerability, pharmacokinetic, and pharmacodynamic study of oral recombinant human interleukin eleven (O-rhIl-11) in normal healthy subjects
179. Consecutive doses of levalbuterol and racemic albuterol result in comparable safety and efficacy: A pharmacokinetic and pharmacodynamic study in mild-moderate asthmatics
180. A pharmacokinetic and pharmacodynamic study with a single implant containing 3-ketodesogestrel (Implanon®)
181. A pharmacokinetic and pharmacodynamic study of NNC 26-0703 in Beagle dogs
182. A pharmacodynamic study of fluoxetine intermittent dosing (pulse loading) for the prophylactic and long-term maintenance treatment of depression
183. D1 Multiple dose safety, pharmacokinetic (PK) and pharmacodynamic study of tasosartan in patients with mild to moderate hypertension
184. The Effects of Acute Renal Failure on Mivacurium-induced Neuromuscular Blockade in the Cat
185. A Model for the Pharmacodynamic Study of Midazolam Administration Through lontophoresis
186. A pharmacodynamic study of the rennin inhibitor SR 43 845, administered intratracheally in conscious cynomolgus monkeys
187. Effects of Succinylcholine on the Pharmacodynamics of Pipecuronium and Pancuronium
188. Comparison of thumb acceleration and thenar EMG in a pharmacodynamic study of alcuronium
189. A Pharmacodynamic Study of the Anthelmintic Properties of Two Oils of Chenopodium
190. Pharmacodynamic Study of the Autonomic Nervous System before and after Thalamotomy
191. A Pharmacodynamic Study of the Pituitary Gland with Tests of a New Product
192. AN INTRAVENOUS PHARMACODYNAMIC STUDY OF THE AUTONOMIC NERVOUS SYSTEM IN THE CRYPTOGENIC GROUP OF CONVULSIVE STATES
193. Pharmacodynamic study of DDT in cockerels
194. A Pharmacodynamic Study of DDT in Rabbits following Acute Intravenous Administration
195. A Pharmacodynamic Study of a Calve’s Plasma Extract
196. Rectal Methohexital for Induction of Anesthesia in Children with and without Rectal Aspiration after Sleep: A Pharmacokinetic and Pharmacodynamic Study
197. DOES INJECTION OF NON-DEPOLARIZING NEUROMUSCULAR BLOCKERS BEFORE THIOPENTONE AFFECT THEIR SPEED OF ONSET?
198. Studies on Morinda citrifolia L. II * *Received August 21, 1959, from the Massachusetts College of Pharmacy, Boston
199. Pharmacodynamic study of the capillaries of normal and allergic (atopic) subjects
200. Preclinical Guidelines for the Testing of New Drugs: Pharmacodynamic Aspects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.